Long-term follow-up for early choroidal melanoma study
Part of Cancer, Eyes & vision clinical trials.
This study follows people who finished a previous trial for a type of eye cancer called early choroidal melanoma. It checks how patients are doing over time after receiving either the study treatment (bel-sar) or a placebo (sham).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been part of the AU-011-301 (CoMpass) study for early choroidal melanoma.
- You must have received either the study drug (bel-sar) or a sham treatment in that study.
- You must be willing and able to agree to take part in this follow-up study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study collects feedback from people already in the CoMpass trial for choroidal melanoma. You'll answer questions about your health and quality of life using a smartphone, laptop, or tablet.
This trial tests a new way to deliver treatment directly into the eye (through a thin space near the choroid) for people whose cancer has spread to the eye. It aims to see if this targeted approach can safely shrink the eye tumors.
This study follows people with high-risk uveal (eye) melanoma after their initial treatment to better understand relapse risk. It may help your care team track you more closely using scheduled visits and blood tests.
This study follows adults with certain melanoma stages to better understand the disease over time. You may be asked to share tissue samples (if available) so researchers can study tumor biology and track outcomes.
This study checks on the long-term health of adults with melanoma who took part in a previous treatment study. It aims to see how participants are doing over time after receiving the new therapy.
This study looks back at past medical records of people diagnosed with uveal melanoma. It helps researchers learn about the typical course of the disease by analyzing what already happened in care.
Hear when a new Choroidal Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.